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Abstract
Background: Studies have shown the existence of p21 induction in a p53-dependent and -independent pathway.
Our previous study indicates that DOX-induced p65 is able to bind the p21 promoter to activate its transactivation
in the cells.
Methods: Over-expression and knock-down experiments were performed in Human Pancreatic Carcinoma (PANC1)
cells. Cell cycle and cell death related proteins were assessed by Western Blotting. Cytotoxicity assay was checked
by CCK-8 kit. Cell growth was analyzed by flow cytometers.
Results: Here we showed that over-expression of p65 decreased the cytotoxic effect of DOX on PANC1 cells,
correlating with increased induction of cytoplasmic p21. We observed that pro-caspase-3 physically associated with
cytoplasmic p21, which may be contribution to prevent p21 translocation into the nucleus. Our data also suggested
that no clear elevation of nuclear p21 by p65 provides a survival advantage by progression cell cycle after treatment
of DOX. Likewise, down-regulation of p65 expression enhanced the cytotoxic effect of DOX, due to a significant
decrease of mRNA levels of anti-apoptotic genes, such as the cellular inhibitor of apoptosis-1 (c-IAP1), and the long
isoform of B cell leukemia/lymphoma-2 (Bcl-2), leading to efficient induction of caspase-3 cleavage in the cells. More,
we present evidence that over-expression of p53 or p53/p65 in the PANC1 cells were more sensitive to DOX
treatment, correlated with activation of caspase-3 and clear elevation of nuclear p21 level. Our previous data
suggested that expression of p21 increases Gefitinib-induced cell death by blocking the cell cycle at the G1 and G2
phases. The present findings here reinforced this idea by showing p21’s ability of potentiality of DOX-induced cell
death correlated with its inhibition of cell cycle progression after over-expression of p53 or p53/p65.
Conclusion: Our data suggested p65 could increase p53-mediated cell death in response to DOX in PANC1 cells.
Thus, it is worth noting that in p53 null or defective tumors, targeting in down-regulation of p65 may well be
useful, leading to the potentiality of chemotherapeutic drugs.
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Background
Pancreatic carcinoma is one of the most leading causes
of cancer mortality in the worldwide. Due to the aggres-
sive nature of the disease and the difficulties in diagno-
sis, the overall 5-year survival rate of pancreatic
carcinoma is less than 5% [1,2]. Pancreatic cancer has
been reported to be resistant to most of chemotherapeu-
tic drugs. The novel approaches for the treatment of
pancreatic cancer are necessary to improve the survival
rate.
Nuclear factor-B (NFB)/p65 are a transcriptional
factor involved in the response to various stimuli and
play a central role in inflammatory reactions. P65 gener-
ally exists as an inactive dimer sequestered in the cyto-
plasm by an inhibitor protein termed IB. Activation of
p65 translocate into the nucleus, where it binds to the
target genes, and promotes transcription [3].
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In response to DNA damage induced by cytotoxic
agents, the tumor suppressor p53 accumulates and func-
tions as a sequence-specific DNA-binding protein, which
positively regulates expression of several genes, includ-
ing p21 (waf1/cip1/sdl1) [4]. P21 is an important cellular
checkpoint protein for G1 and G2 arrest [5-7].
It is widely accepted that p21 is induced by p53-
dependent and p53-independent pathway. We and other
group reported that a novel potential NFB/p65 binding
site is at position -2008 of the p21 promoter and the
binding of NFB/p65 protein to this B site results in
transactivation of p21 promoter by p65 [8,9].
Doxorubicin (DOX) is the most widely used che-
motherapy agent in treatment of tumor. DOX targets
DNA topoisomerase II enzyme activity, which involves
sequential DNA binding, cleavage of DNA phosphodie-
ster backbone and subsequently causes DNA breaks.
Recent data suggest that DOX-induced cell death is
interconnected with the machinery of cell cycle control.
Progression through G1 or G2 phase and entry into the
S or M phase are tightly regulated by cyclin-dependent
kinases (CDKs). Alterations in cell cycle control are a
universal feature of cancers. Our previous data sug-
gested that the abnormal progression of cell cycle
related with p21 is responsible for DOX-induced cell
death [10-13].
Genetic and biochemical studies indicate that DOX-
induced cell death is triggered by activation of the mem-
bers of caspase protease family [14-16]. Activation of
caspases during apoptosis converts the inactive, pro-
enzyme forms of caspases into the active, processed
forms which in turn cleave downstream substrates, lead-
ing to biochemical events such as DNA fragmentation
[17]. Caspase-3 has been implicated in playing a critical
role during apoptosis. Although many molecular path-
ways are involved in the apoptosis-regulatory mechan-
ism, evidence suggests that the cell cycle and DOX-
induced cell death may be involved.
In this study, we showed that the over-expression of
p65 remarkably decreased the cytotoxic effect of DOX
on Human Pancreatic Carcinoma (PANC1) cells, corre-
lating with the increasing of induction for cytoplasmic
p21. In contrast, the reduction of p65 by knock-down of
p65 enhanced the cytotoxic effect of DOX treatment
due to the increase of activation of caspase-3. We also
documented that Induction of p65 enhanced the p53-
mediated cell death response to DOX in PANC1 cells.
Methods
Cells and transfection
Human Pancreatic Carcinoma (PANC1) cells were cul-
tured in DMEM medium supplemented with 10% FBS
(Hyclone, logan, UT). Myc-p21-pcDNA4 and pcDNA4-
p53 expression vector were generated as described ref7.
ShRNA sequence against p65 (CAA AAA AAG GTC
ATG GAC GGT CTA TCT CTT GAA TAG ACC GTC
CAT GAC CTTT and TCC CAA AGG TCA TGG
ACG GTC TAT TCA AGA GAT AGA CCG TCC
ATG ACC TTTT) were clone into pSUPER-EGFP1 con-
structs (OligoEngine, Seattle, WA). The pSUPER-Scram-
ble plasmid (gat ccc cTT CTC CGA ACG TGT CAC
GTt tca aga gaA CGT GAC ACG TTC GGA GAA ttt
ttg gaa a) was used as the nonsense control [18]. Cells
were transiently transfected with expression constructs
using Lipofectamine 2000 reagent (Invitrogen, Carisbad,
CA).
Measurement of cell death
Cells were seeded into 96-well plates and transiently
transfected 12 h with expression constructs for p65, p53
or shRNA-p65, followed by DOX treatment (2 μg/ml)
for 24 h. Then 10 μl of the CCK-8 solution was added
to each well of the plates and then incubated for 2 h in
the incubator (37°C and 5% CO2). Cytotoxicity assay
could be used with the CCK-8 solution according to the
procedure of Cell Counting Kit-8 (Dojindo Laboratories,
Tokyo, Japan). The absorbency was measured at 450 nm
using a micro-plate reader (BioTeK).
Western Blotting and Immunoprecipitation
The nuclear and cytoplasmic extract from the cells were
prepared by the Nuclear Extract Kit (Active Motif,
Carlsbad, CA). The protein content of the cell lysate
was determined by using the Bradford calorimetric assay
method (Bio-Rad, Richmond, CA). The 40 μg aliquot of
cytoplasmic or nuclear lysate were resolved by 12%
polyacrylamide-sodium lauryl sulfate gel electrophoresis
and transferred to a Hybond-C Super membrane (Amer-
sham, Buckinghamshire, UK). The antibodies against
p65 (8242, Cell Signaling), pro-caspase-3 (9665, Cell Sig-
naling), active-casepase-3 (9664, Cell Signaling), p53
(9282, Cell Signaling), p21 (2946, Cell Signaling), CDK2
(2546, Cell Signaling), CDK4 (2906, Cell Signaling),
cyclinD1 (2922, Cell Signaling), cyclinE (4129, Cell Sig-
naling), Myc (46-0603, Invitrogen) and GAPDH
(AG019, Beyotime) were used. Then the blot was incu-
bated with a secondary antibody, IRDye 800 conjugated
affinity purified anti-mouse or anti-rabbit IgG (Rockland
Immunochemical, Inc., Gilbertsville, PA) and detected
with Odyssey Infrared Imaging System (LI-COR Bios-
ciences, Nebraska, USA). For immunoprecipitation, a
500 μg aliquot of cell lysate was incubated for 1 h at 4°
C with the anti-p21 anti-body (2946, Cell Signaling).
Immune complexes were captured by incubation with
80 μl protein G-plus-agarose (Santa Cruz Biotechnology,
Santa Cruz, CA) for 10 h, then washed several times
with NP-40 buffer and lysed with loading buffer to do
Western Blotting analysis.
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Cell growth analysis
Cells were washed twice with PBS, trypsin zed and re-
suspended in PBS containing 0.1% Triton X-100 and
RNase (1 mg/ml) (Sigma, St Louis, MO). The cell suspen-
sion was incubated at 37°C for 30 min. Propidium iodide
(Molecular Probes, Inc. Eugene, OR) was added at a final
concentration of 50 μg/ml and the cell suspension was
kept at 4°C for 1 hour. The cells were filtered and the cell
cycle was analyzed by flow cytometry with the FACScan
system (Becton Dickinson, Franklin Lakes, NJ).
mRNA expression
Total RNA of the cells were extracted by homogeniza-
tion in 1 mL TRIzol reagent (Invitrogen, Carlsbad CA,
USA), followed by chloroform re-extraction and isopro-
panol precipitation. The RNA was quantified with
Eppendorf Biophotometer (Eppendorf, Hamburg, Ger-
many). 0.5 μg of total RNA were reverse transcribed
using PrimeScriptTM RT reagent Kit (DRR037A,
Takara). Real-time PCR analysis was done using pri-
mers: Bcl-2, forward: ACC TGC ACA CCT GGA
TCCAG; reverse: CTT GTG GCC CAG ATA GGCAC;
cIAP-1, forward: CCT GAG CAG CTT GCA AGTGC;
reverse: TGA CGG ATG AAC TCC TGTCC. The aver-
age of genes was normalized to the levels of GAPDH:
forward: GGT CGT ATT GGG CGC CTG GTC ACC,
reverse: CAC ACC CAT GAC GAA CAT GGG GGC.
Results
Cytoplasmic p21 induced by p65 is necessary to prevent
DOX-induced cell death in PANC1 cells
NFB/p65 is a transcription factor that can protect or
contribute to apoptosis [19]. To examine the effect of
p65 in this study, we transfected with p65 into PANC1
pancreatic cancer cells and detected remarkably increas-
ing of p65 expression in the cells (Figure 1A). Likewise,
we used p65-targeted shRNA to silence p65 expression
in PANC1 cells. As seen in Figure 1A again, cells trans-
fected with p65-targeted shRNA showed a strong reduc-
tion of endogenous p65 expression. Then, the rate of
cell survival after treatment with cytotoxic drug DOX (2
μg/ml, 24 h treatment) was shown in Figure 1B. When
the PANC1 cells were forced to express p65-targeted
shRNA, the percentage of DOX-induced cell death were
remarkably increased as compared to control shRNA. In
contrast, over-expression of p65 reduced the DOX-
induced cell death as compared to vector in PANC1
cells. These data suggested that target in reduction of
p65 expression in PANC1 pancreatic cancer cells was
useful, leading to the potency of DOX-treatment.
It is the known fact that the expression level of p21
increased in p53-dependent or p53-independent path-
way. In previous studies, we showed that p65 increases
p21 expression by binding to p21 promoter B site and
p21 (waf1/cip1) is involved in DOX-induced cell death
[9]. To investigate the role of p21 in this study, we
assessed the cytoplasmic and nuclear levels of p21 in
PANC1 cells. As shown in Figure 1C, the cytoplasmic
p21 protein expression level in the cell extract was sig-
nificantly elevated in PANC1 cells after transfection
with p65 expression vector followed by DOX treatment
for 24 h. However, the nuclear p21 was not changed, as
compared to the control vector. In contrast, both cyto-
plasmic and nuclear levels of p21 were not changed
when PANC1 cells were forced to express p65-targeted
shRNA (Figure 1C).
A family of aspartate-specific cysteine proteases (cas-
pases) plays a pivotal role in the execution of pro-
grammed cell death. To gain insight into the
involvement of caspases in DOX induced cell death in
this study, we investigated the effects of p65 expression
status on the activation of caspase-3. The protein
expression of pro-caspase-3 and active caspase-3 was
assessed by Western blotting in PANC1 cells that were
treated with DOX at 24 h following p65 over-expression
or down-regulation transfection. As shown in Figure 1C
again, pro-caspase-3 was significantly elevated in
PANC1 cells after transfection with p65 expression vec-
tor followed by DOX treatment, as compared to control
vector. More, activation of caspase-3 protease cleavage
after DOX treatment was suppressed in this condition.
In contrast, when the cells were transfected with p65-
targeted shRNA, the activation of caspase-3 was
increased (Figure 2A). These results demonstrated that
activation of caspase-3 was associated with DOX-
induced cell death in PANC1 cells (Figure 1B and 1C).
Pro-caspase-3 physically associated with cytoplasmic p21
induction by p65 in PANC1 cells
The results described above suggest that cytoplasmic
p21 induced by p65 prevented cell death induced by
DOX treatment in PANC1 cells. We then examined
whether there is a biochemical interaction between cyto-
plasmic p21 and pro-caspase-3 in PANC1 cells. The
cytoplasmic p21 proteins were immunoprecipitated
from those cells extract using an anti-p21 antibody. The
immunoprecipitates were examined by Western blotting
with an anti-pro-caspase-3 antibody and an anti-p21
antibody. As shown in Figure 2A, the association
between cytoplasmic p21 and pro-caspase-3 was found
to remarkably increase when the cells were forced to
transiently over-express p65, but not down-regulation of
P65. To ask which parts of the p21 participate in inter-
acting with pro-casepase-3. We used with wild-type p21
(1-585), the N-terminal domain of p21 (1-372) and the
C-terminal domain of p21 (373-585) expression vectors.
These Myc-tagged recombinant p21 proteins were
immunoprecipitated from those cells using an anti-Myc
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peptide antibody. The immunoprecipitates were exam-
ined by Western blotting with an anti-pro-caspase-3
antibody and an anti-p21 antibody. Wild-type p21 and
the N-terminal domain were found to interact with pr-
caspase-3 while the C-terminal domain failed to associ-
ate with caspase-3 (Figure 2B). Thus, our results indicate
that existing inactivated pro-caspase-3 may prevent p21
translocation from cytoplasm to nucleus by physically
associating with cytoplasmic p21 induced by over-
expression of p65.
Next, we were interested in confirming that the effects
of the down-regulation of P65 could be seen with p65-
regulated target genes. For these experiments, we analyzed
cIAP-1 and Bcl-2, which are anti-apoptotic genes regu-
lated by p65. The real-time PCR analysis of RNA extracted
from PANC1 cells when the cells were forced to transi-
ently over-express p65 or p65-targeted shRNA. As seen in
Figure 3, cIAP-1 and Bcl-2 mRNA levels remarkably
increased in PANC1 cells with the over-express p65. In
contrast to these observations, down-regulation of P65
Figure 1 Cytoplasmic p21 induced by p65 is necessary to prevent the activation of procaspase-3 in PANC1 cell. Cells were transiently
transfected with or without over-expression of p65 and p65-targeted shRNA followed by DOX treatment (2 μg/ml) for 24 h. (A) The level of p65
protein was detected by Western blotting. (B) Cell survival was examined by CCK8 kit. Error bar indicates the standard error of the mean of three
independent experiments. (C)The nuclear or cytoplasmic p21 protein (above) and pro-caspase-3 or active caspase-3 (bottom) were detected by
Western blotting. GAPDH was used as controls.
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resulted in decrease in cIAP-1 and Bcl-2 mRNA levels as
compared with its parental PANC1 cells (Figure 3). It led
us to suggest that PANC1 cells with down-regulation of
P65 were more sensitive to DOX treatment may partly
due to decreasing expression of these anti-apoptotic genes.
We further sought to test some other key cell cycle
regulators which also showed in Figure 1C. Thus, we
observed no remarkably change in the levels of cdk2,
cdk4, cyclinE and cyclinD1 by DOX in PANC1 cells
with reduction or over-expression of p65 (Figure 4A).
These data was consistent with results of cell cycle ana-
lysis showed that no change in the cell cycle pattern of
these cells after regulating expression of p65 (Figure
4B). Our data suggested that no clear elevation of
nuclear p21 by p65 provides a survival advantage by
progression cell cycle after treatment of DOX.
Induction of p65 enhanced the p53-mediated cell death
response to DOX in PANC1 cells
P53 tumor suppressor is known to play an important
role in mediating DNA damage agent’s induced-cell
death through a variety of mechanisms [20-22]. To con-
firm this point, we over-expressed p53 into PANC1 pan-
creatic cancer cells which are endogenous p53-negative
(Figure 5A). Next, we used DOX to treat PANC1 (p53+
+) cells and its parental cells for 24 h. As shown in Fig-
ure 4B, DOX-induced cell death was remarkably higher
in PANC1 (p53++) cells than in its parent cells. This
result suggests a requirement of p53 for DOX-induced
cell death PANC1 pancreatic cancer cells.
Then we want to check p65 effects on the cells of
over-expression of p53, and co-transfected with p53 and
p65 into the cells. As shown in Figure 5A again, a clear
elevation level of p53 or p65 was seen as compared to
the control vector. Furthermore, cell survival rate was
decreased after forced over-expression p53 and p65, as
compared to the cells transfected with p53 alone (Figure
5B). These data led us to suggest that induction of p65
specifically enhanced the p53-mediated cell death
response to DOX.
To investigate the role of p21 in this case, we assessed
cytoplasmic and nuclear levels of p21 in these cells. As
shown in Figure 5C, the nuclear p21 protein expression
level in the cell extract was significantly elevated in
PANC1 cells after transfection with p53 or p53/p65
over-expression vector followed by DOX treatment for
24 h. Moreover, the amount of cytoplasmic p21 likely
corresponded to its pattern in nucleus (Figure 5C).
Next, we investigated the effects of the activation of
caspase-3 on reduction cytoplasmic p21. The cytoplas-
mic p21 proteins were immunoprecipitated from those
cells extract using an anti-p21 antibody. The immuno-
precipitates were examined by Western blotting with an
anti-pro-caspase-3 antibody and an anti-p21 antibody.
As shown in Figure 5C again, the association between
cytoplasmic p21 and pro-caspase-3 was found to
remarkably reduce when the cells were forced to transi-
ently over-express p53 or p53/p65. These results indi-
cate that over-expression of p53 mediated caspase-3
activation, which may prevent pro-caspase-3 to physi-
cally associate with cytoplasmic p21 and then promoted
it translocation from the cytoplasm to nucleus.
More, the protein expression of active caspase-3 was
assessed by Western blotting assay. As shown in Figure
5D, active-caspase-3 was significantly elevated in
PANC1 cells after transfection with p53 or p53/p65
expression vector followed by DOX treatment, as com-
pared to control vector.
Next, we sought to test some other key cell cycle reg-
ulators which also showed in Figure 6A. Thus, we
observed remarkably reduction in the levels of cdk2,
cdk4, cyclinE and cyclinD1 by DOX after transfection
with p53 or p53/p65 over-expression vector. To exam-
ine the change in the cell cycle pattern of these cells,
the flow cytometry was carried out (Figure 6B). As
expected, in PANC1 (p53++) and (p53++/p65++) cells
fractions of G1-phase cells were increased from 54 and
49 to 79% and 76%, indicating the cell cycle is arrested
at G1-phase due to increasing of nuclear p21 expression.
These data suggest data that nuclear p21 induction by
p53 promotes cell death may also due to its ability to
Figure 2 Pro-caspase-3 physically associated with cytoplasmic
p21 induction by p65 in PANC1 cells. (A) Cells were transiently
transfected with or without over-expression of p65 and p65-
targeted shRNA followed by DOX treatment (2 μg/ml) for 24 h.
Whole cell extract was subjected to immunoprecipitation with anti-
p21 antibody and then immunoblotted with anti-pro-caspase-3 or
-active-caspase-3 antibody. (B) Cells were transfected with vector
expressing wild-type (1-585), N-terminal (1-372) and C-terminal (373-
585) region of p21 followed by DOX treatment (2 μg/ml) for 24 h.
Immunoprecipitation with an antibody against myc peptide. The
pro-caspase-3 and p21 amounts were assessed by Western blotting.
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stop cell cycle progression, which at least partly contri-
butes to DOX-induced cell death in p53-dependent way.
Discussion
In this study, we showed that the over-expression of p65
remarkably decreased the cytotoxic effect of DOX on
PANC1 cells. That correlated with the increasing of
induction of cytoplasmic p21. We observed that pro-cas-
pase-3 physically associated with cytoplasmic p21, which
may prevent p21 translocation from cytoplasm. In con-
trast, down-regulation of p65 enhanced the cytotoxic
effect to DOX treatment, due to activation of cleavage
of caaspase-3 in the cells. More, we present evidence
that over-expression of p53 or p53/p65 in the PANC1
cells were more sensitive to DOX treatment, correlated
with activation of caspase-3 and clear elevation of
nuclear p21 level. Our data suggested p65 could increase
p53-mediated cell death in response to DOX in PANC1
cells.
P65 is involved in the regulation of cell death in sev-
eral systems [19]. In this study, we found that over-
expression of p65 remarkably decreased the cytotoxic
effect of DOX on PANC1 cells. In contrast, down-regu-
lation of p65 increased DOX-induced cell death in the
cells (Figure 1A and 1B). These observations suggest
that a regulatory mechanism for p65 must exist to inte-
grate and coordinate its critical cellular decision-making
event. Studies have shown the existence of p21
Figure 3 Down-regulation of p65 reduced expression of the anti-apoptotic genes. Cells were transiently transfected with or without over-
expression of p65 and p65-targeted shRNA. Real-time PCR was performed to assess c-IAP1 (above) and BCL-2 (bottom) mRNA in the cells with
GAPDH as control. Error bar indicates the standard error of the mean of three independent experiments.
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induction in a p53-independent pathway. Our previous
study indicates that DOX-induced p65 is able to bind
the p21 promoter to activate its transactivation in the
cells. Here we observed p21 induction in p65-dependent
mechanism in response to DOX (Figure 1C). Thus, we
suggested that induction of p21 by p65 is at least partly
responsibility to decrease of DOX-induced cell death in
the cells.
Genetic and biochemical studies indicate that DOX-
induced cell death is triggered by activation of the mem-
bers of caspase protease family [14,16-18,22]. Caspase-3
plays a pivotal role in the execution of DOX-induced
cell death. We and other groups have reported that p65
prevents drugs-induced cytotoxic action by blocking cas-
pases protease activation [8,9]. These results are consis-
tent with our finding that down-regulation of p65
expression was preceded by > 3-fold reduction of c-
IAP1 and Bcl-2 mRNA expression in PANC1 cells (Fig-
ure 3), suggesting that the decreasing expression of
some anti-apoptotic genes contributed to increasing sen-
sitive to DOX-induced cell death. Here, our results indi-
cated that existing inactivated pro-caspase-3 by p65 may
prevent p21 translocation from cytoplasm into nucleus
by physically associating with cytoplasmic p21 (Figure
2A and 2B). These data are consistent with those of
recent studies showing that pro-caspase-3/p21 complex
formation could resist cell death in human tumor cells
[15-17]. More, our data suggested that no clear elevation
of nuclear p21 by over-expression p65 provides a survi-
val advantage by progression cell cycle after treatment
of DOX (Figure 4A and 4B).
PANC1 pancreatic cancer cells are endogenous p53-
negative. Thus, our data suggest that induction of p65
in p53 null tumors provides a survival advantage by
physically associating with procaspase-3 and preventing
p21 translocation from cytoplasm to nucleus in PANC1
cells treated with DOX. On the other hand, it is worth
noting that in p53 null or defective tumors, targeting in
down-regulation of p65 was found to augment an effec-
tive therapeutic response to DOX.
In this study, we showed that pancreatic tumor cells
that have over-expression of p53 were more sensitive to
DOX-induced cell death (Figure 5A and 5B), correlated
with activation of caspase-3 whose induction by DOX in
the p53-dependent pathway (Figure 5C). The mechan-
ism through which p53 promotes cell death is also
dependent on the Apaf-1/caspase-9 pathway and
involves cytochrome C releasing from mitochondria
[20]. Several potential downstream mediators such as,
CD95, Killer/DR5, PERP, p53AIP1 and Bax are involved
in p53-dependent cell death [21,22]. Taken together, we
propose that p53 is required for DOX-induced cell
death in PANC1 pancreatic cancer cells.
Here, we observed that in response to DOX, p21 level
was induced by over-expression of p53 or p53 and p65.
Moreover, p53 induced caspase-3 to cleavage to its
active form after treated with DOX even occurred to
co-transfection with p65. Much less physically associat-
ing with procaspase-3 promoted p21 translocation from
cytoplasm to nucleus, as evidenced by a clear elevation
of nuclear p21 level induced by p53 or p53 and p65
(Figure 5D). However, the biochemical basis of the p21
translocation from cytoplasm to nucleus related with
caspase-3 should be clarified in the further studies.
DOX induces both cell cycle arrest and apoptosis,
although the detailed mechanism whereby DOX com-
mits cells to apoptotic program is unknown. It has been
postulated that the imbalance of the cell cycle signals or
failure to arrest the cell cycle may trigger the cell death
program. Our previous data suggested that expression of
p21 increases Gefitinib-induced cell death by inactiva-
tion of cyclin-dependent kinase (CDK) activity, which in
turn blocks the cell cycle at the G1 and G2 phases [12].
The present findings here reinforced this idea by show-
ing p21’s ability of potentiality of DOX-induced cell
death correlated with its inhibition of cell cycle progres-
sion after over-expression of p53 or p53/p65 (Figure 6A
and 6B).
Figure 4 Change of P65 status was not related cell cycle
pattern in PANC1 cells. Cells were transiently transfected with
or without over-expression of p65 and p65-targeted shRNA
followed by DOX treatment (2 μg/ml) for 24 h. (A) The level of
CDK2, CDK4, and cyclinD1 or cyclinE protein were detected by
Western blotting. GAPDH was used as controls. (B) Cell cycle
pattern. Error bar indicates the standard error of the mean of three
independent experiments.
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P53 plays an important role in the tumor therapy.
However, it is reported that more than 60% human
tumors have lost their wild-type p53 function. Increas-
ing evidence suggests that deficiency of p53 in tumors
constitutes resistance to chemotherapy and anti-angio-
genic treatment. Hence, efforts have been made to
improve the efficacy of anti-tumor therapy on the
tumors deficient in p53 expression. Here we suggested
that in tumor cells that are p53-null or defeated, down-
regulation of p65 may well be useful, leading to the
potentiality of chemotherapeutic drugs.
However, in tumors that retain wild-type p53, such
targeting may be counterproductive, because p65 poten-
tiality of p53-mediated cell death in this study. The
tumor suppressor p53 inhibits cell growth through acti-
vation of cell-cycle arrest and apoptosis. Our previous
data suggested that p65-induced anti-apoptotic gene
expressions are much higher in p53-/- cells than in p53
+/+ cells. We and other groups found that the transcrip-
tional activities of p53 and p65 are governed by their
relative levels of expression: p65 inhibits p53-dependent
transactivation, while p53 expression can also suppress
p65 transcriptional activity [8,9]. P53 could limit p65-
mediated transactivation and this mutual repression
mechanism is due to their limiting common co-activa-
tors (p300 and CBP) of transcription [23-26]. Thus, we
could speculate that p65 loss the ability to promote to
induce anti-apoptotic gene expressions, then turn into
pro-apoptotic process in p53+/+ cells, which contributes
to p65 augmenting an effective therapeutic response to
DOX in p53-mediated way.
Conclusion
In the present study, we observed that the p21 expres-
sion level was a key player in the cell cycle and DOX-
induced cell death process. The clear elevation of
nuclear p21 expression by p53 or p53 and p65 may pro-
vide a good rationale for promoting to DOX treatment
in Human Pancreatic Carcinoma. Thus, we propose that
it may be important in the design of therapeutic proto-
cols that involve targeting of p21 to mediate pancreatic
tumor’s sensitivity to the drugs.
Figure 5 Induction of p65 enhanced the p53-mediated cell death response to DOX in PANC1 cells. Cells were transiently transfected with
or without over-expression of p53 alone or p53 and p65 together followed by DOX treatment (2 μg/ml) for 24 h. (A) The level of p53 or p65
protein was detected by Western blotting. (B) Cell survival was examined by CCK8 kit. Error bar indicates the standard error of the mean of three
independent experiments. (C)The nuclear or cytoplasmic p21 protein (above) or pro-caspase-3 (bottom) were detected by Western blotting.
GAPDH was used as controls. Whole cell extract was subjected to immunoprecipitation with anti-p21 antibody and then immunoblotted with
anti-pro-caspase-3 antibody (middle). (D) Active-caspase-3 and active-caspase-8 protein were detected by Western blotting. GAPDH was used as
controls.
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